Lv1
10 积分 2021-06-23 加入
Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
1个月前
已完结
Advancements in Bispecific Antibodies for Multiple Myeloma: What's New and What Lies Ahead
1个月前
已完结
An evaluation of linvoseltamab for treatment of relapsed/refractory multiple myeloma
2个月前
已完结
CAR-T cell targeting three receptors on autoreactive B cells for systemic lupus erythematosus therapy
2个月前
已完结
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
2个月前
已完结
The TNF family members BAFF and APRIL: the growing complexity
3个月前
已完结
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment
3个月前
已完结
Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52‐Week Results From a Randomized, Placebo‐Controlled, Phase 2b Dose‐Ranging Study
3个月前
已完结
BAFF-R, the major B cell–activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders
3个月前
已完结
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial
3个月前
已完结
皖公网安备34019202002308
